Global Access Atlas

Filters

Choose one market

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Norway

DMP handles regulatory, maximum-price and assessment functions, but community blue-prescription funding and hospital Nye metoder decisions follow different routes. Hospital price negotiation precedes Decision Forum approval.

DMP / EC-EMA under EØS

DMP

company / DMP / Nye metoder Bestillerforum

DMP

DMP / HELFO / prescriber / pharmacy

8 decision nodes13 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it

Evidence checked through 2026-08-06A pathway is a decision map—not a launch-time promise

Locate the relevant route first

These choices define how to read the branches below. They do not predict a payer or provider decision.

1

Who funds the Norwegian medicine?Funding responsibility selects the decision chain.

Selected routeBlue prescription8 applicable nodes

Authorization-to-patient timeline

See the selected route reach the patient

Updates immediately when a choice changes

1

Norway-valid marketing authorisationmaximum price and funding route

2

Maximum-price determinationfunding economics and pharmacy sale

3

Funding-route requestDMP method assessment

4

DMP method assessmentblue-resept decision or hospital negotiation/decision

5

Folketrygden reimbursement decision and claimcontinuing outpatient access

6

First funded patientEligible patient + capable provider + authorization + product + clean payment

1Assign the funding owner

2Complete DMP evidence and Sykehusinnkjøp negotiation

3Confirm effective Decision Forum status

4Activate price file, contract and hospital stock

Do not collapse these decisions

DMP assessment, introductory price negotiation, Decision Forum approval, procurement and technical price-file activation are separate milestones.

Decision map

What each local node actually produces

Select a row to inspect legal effect and downstream gates

#Local decision / ownerDecision outputDownstream dependencyEvidence

Decision question

Are quality, safety and efficacy sufficient for the claimed indication?

Required evidence / materials

CTD, benefit-risk, RMP, Norwegian product information

Can iterate or branch

national, CP/DCP/MRP, variation, renewal

Source date

NO-S01 · current procedure

Node linked to cited dossier sourcesProduct/provider execution still requires live verification

Special mechanisms and lifecycle

What can reopen price, coverage or procurement after launch

Dates below come from the cited policy record—not a product forecast

Mechanism / triggerDecision outputIteration / branchPolicy recordLatest observed

Price-file, procurement, first patient and lifecycleactive price/contract, local adoption, treated/paid patienttwice-monthly files, tender, access scheme, reassessment, shortageNO-S09 · NO-S10 · NO-S11published 2026

New-indication method assessmentBlue-prescription reassessmentLIS tender renewalMaximum/step-price adjustment

Evidence & policy library

Official basis and policy dates

13 records · checked 2026-08-06

NO-S01 · DMP · Søknad og oppfølging av markedsføringstillatelsePolicy / effective: current procedure · Latest observed 2026-05-21MA requirements, output and post-authorisation duties NO-S02 · DMP · MaksimalprisPolicy / effective: current price method · Latest observed 2026-07-01 price filemaximum AIP/AUP, actual/hospital discount distinction NO-S03 · DMP · Anmodning og forslag for blåreseptlegemidlerPolicy / effective: effective 2026-07-01 · Latest observed 2026-07-02indication-specific requests, reassessment and price update NO-S04 · DMP · Offentlig finansiering av legemidler og medisinsk utstyrPolicy / effective: current framework · Latest observed page current at checkfunding split, priority criteria and DMP decision remit NO-S05 · DMP · Retningslinjer for dokumentasjonsgrunnlag for metodevurdering av legemidlerPolicy / effective: requirements effective 2026-07-06 · Latest observed 2026-07-07must/should evidence, HE method and EQ-5D requirement NO-S06 · Nye metoder · Hvem gjør hva i Nye metoderPolicy / effective: current governance · Latest observed page current at checkBestillerforum, DMP/FHI and Beslutningsforum roles NO-S07 · DMP · Saksbehandlingsstatus for metodevurderinger av legemidlerPolicy / effective: current status/target · Latest observed 2026-07-13180-day target and clock stop NO-S08 · Nye metoder · Spørsmål og svar om Nye metoder og BeslutningsforumPolicy / effective: current governance · Latest observed page current at checkpriority criteria, actors, price negotiation and final decision NO-S09 · Nye metoder · Forholdet mellom Nye metoder og anskaffelserPolicy / effective: current process · Latest observed published 2026negotiation, procurement, contract/master data and 2–15 days NO-S10 · Nye metoder · ImplementeringPolicy / effective: current implementation · Latest observed 2024-08-13accepted price registration, LIS notification and twice-monthly files NO-S11 · Nye metoder · TilgangsordningenPolicy / effective: current scheme · Latest observed published 2026post-non-introduction patient exception NO-S12 · DMP · Anbud på blåresept-legemidler and selection criteriaPolicy / effective: permanent scheme from 2023 · Latest observed 2025-09-19 / 2025-04-01outpatient tender, criteria and patient continuity NO-S12 · DMP · Anbud på blåresept-legemidler and selection criteriaPolicy / effective: permanent scheme from 2023 · Latest observed 2025-09-19 / 2025-04-01outpatient tender, criteria and patient continuity NO-S13 · Nye metoder · Retningslinje for compassionate use before marketing authorisationPolicy / effective: current guideline · Latest observed published 2026pre-authorisation exception and agreement boundary